According to Data Bridge Market Research new Market report, “Global Performance Enhancing Drugs Market
• By causative agent (Mycoplasma, Virus),
• By Treatment type (drug, Vaccines),
• by Route of Administration (Oral and Parenteral),
• Distribution channel (Hospitals, Pharmacies),
• Geography – Industry Trends and Forecast to 2025’’ global Performance Enhancing Drugs market accounted to USD xx million in 2017 growing at a CAGR of 4.8% during the forecast period of 2018 to 2025.
Performance enhancing drugs are chemical agents designed to provide an advantage in athletic performance. Muscle enlargement, increased blood’s oxygen carrying capacity is some of the effects induced by the consumption of the performance enhancing drugs.
Performance enhancing drugs market is increasing in the presence of well-developed economies with high per capita income, these are also used the treatment of certain types of breast cancer.
Market Segmentation: Global Performance Enhancing Drugs Market
The global performance enhancing drugs market is segmented on the basis of types, products, and end users.
• By Types
• ergogenic aids
• anabolic steroids
• dehydroepiandrosterone (DHEA)
• human growth hormone
• others
• nootropic
• racetams
• ampakines
• choline & acetylcholine intermediates
• others
• by Product
• Pills
• Injections
• patches
• others Vaccines
• by End users
• athletes
• body builders
• students
• militaries
Geographical Segmentation: Global Performance Enhancing Drugs Market
• North America
• South America
• Europe
• Asia-Pacific
• Middle East and Africa
FACTORS DRIVING GROWTH IN THE PERFORMANCE ENHANCING DRUGS MARKET
Well-developed economy
The Americas dominates the global performance enhancing drugs market owing to the presence of well-developed economies with high per capita income within the region like the U.S. and Canada.
New cases of invasive cancer patients
In 2017, according to the American Cancer Society in the U.S., about 252,710 new cases of invasive breast cancer diagnosed in women. Moreover, it is predicted that by the end of 2017, 40,610 women would die from breast cancer. This will boost the market growth during the forecasted period as anabolic steroids can be for the treatment of certain types of breast cancer.
Growing focus of market players
The global Performance Enhancing Drugs market report contains an in-depth profiling of the key market players, along with the recent developments (new product launches, partnerships, agreements, collaborations, and joint ventures) and strategies adopted by them to sustain and strengthen their position in the market. The report also covers the market shares for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America bleeding disorder treatment market.
Some of the major players operating in global Performance Enhancing Drugs market are
• Taj Pharmaceuticals Limited. (India),
• Balkan Pharmaceuticals. (Europe),
• Bayer AG (Europe),
• AstraZeneca (Europe),
• Novo Nordisk A/S (Europe),
• BrainAlert, LLC (U.S.),
• Douglas Laboratories. (U.S.),
• Onnit Labs, LLC. (U.S.),
• Eli Lilly and Company. (U.S.).
About Us:
Data bridge Market Research is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our client’s needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few
Contact Us:
Data Bridge Market Research
Toll Free: +1-888-387-2818
Email - [email protected]